Overview of liposarcomas and their genomic landscape

Abstract

Liposarcoma (LPS) is among the most common soft tissue sarcoma affecting adults. LPS is divided into three biologic subtypes characterized by specific genetic alterations. The most common LPS subtypes, well-differentiated and dedifferentiated LPS, are nearly uniformly characterized by ring chromosomes and giant markers with chromosomal amplification of 12q13-15 and resulting amplification of oncogenes MDM2, CDK4, and HMGA2. Myxoid/round cell LPS commonly exhibits a distinctive (12; 16) translocation resulting in the FUS-DDIT3 fusion gene. Finally, pleomorphic LPS harbors diverse complex genomic changes and chromosomal rearrangements and frequent mutations in TP53, RB1, and NF1 leading to dysregulation of tumor suppressor pathways. In this review, we summarize the currently available knowledge on the genomics and genetics of LPS subtypes as well as recent advances in the multimodality management of LPS.

Keywords

Dedifferentiated liposarcoma / liposarcoma / genetics / genomics / myxoid liposarcoma / pleomorphic liposarcoma / round cell liposarcoma / well-differentiated liposarcoma

References

[1] Crago AM.Liposarcoma: multimodality management and future targeted therapies..Surg Oncol Clin N Am2016;25:761-73 PMCID:PMC5010855

[2] Crago AM.Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma..Curr Opin Oncol2011;23:373-8 PMCID:PMC3253354

[3] Abeshouse A,Adebamowo SN,Akeredolu T.Comprehensive and integrated genomic characterization of adult soft tissue sarcomas..Cell2017;171:950-65.e28 PMCID:PMC5693358

[4] Jones RL,Thway K.Clinical and molecular spectrum of liposarcoma..J Clin Oncol2018;36:151-9 PMCID:PMC5759315

[5] Somaiah N,Barbo A,Wang WL.Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations..Oncotarget2018;9:19891-9 PMCID:PMC5929434

[6] Haupt Y,Kazaz A.Mdm2 promotes the rapid degradation of p53..Nature1997;387:296-9

[7] Kubbutat MH,Vousden KH.Regulation of p53 stability by Mdm2..Nature1997;387:299-303

[8] Zhang Z,Li M,Agrawal S.Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway..Oncogene2005;24:7238-47

[9] Jin Y,Zeng SX,Lu H.MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation..EMBO J2003;22:6365-77 PMCID:PMC291841

[10] Wang SP,Chang YL,Chao YC.p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug..Nat Cell Biol2009;11:694-704

[11] Kanojia D,Garg M,Sato A.Genomic landscape of liposarcoma..Oncotarget2015;6:42429-44 PMCID:PMC4767443

[12] Barretina J,Banerji S,Lagos-Quintana M.Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy..Nat Genet2010;42:715-21 PMCID:PMC2911503

[13] Beird HC,Ingram DR,Alimohamed A.Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin..Cold Spring Harb Mol case Stud2018;4:pli:a002386 PMCID:PMC5880260

[14] Chibon F,Derré J,Coindre JM.A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas..Cancer Genet Cytogenet2002;139:24-9

[15] Chibon F,Derré J,Coindre J-M.ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications..Genes Chromosomes Cancer2004;40:32-7

[16] Mariani O,Coindre JM,Ganem C.JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas..Cancer Cell2007;11:361-74

[17] Asano N,Mitani S,Shiotani B.Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma..Oncotarget2017;8:12941-52 PMCID:PMC5355068

[18] Taylor BS,Angeles CV.,Schultz N.Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas..Cancer Discov2011;1:587-97 PMCID:PMC3274776

[19] Li C,Ren Y,Li M.Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma..Hum Pathol2016;55:143-50

[20] Nakazawa MS,Sadri N,Gade TPF.Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth..Nat Commun2016;7:10539

[21] Keung EZ,Al Sannaa GA,Lev D.Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma..J Clin Invest2015;125:2965-78 PMCID:PMC4742834

[22] Smolle MA,Posch F,Liegl-Atzwanger B.MicroRNAs in different histologies of soft tissue sarcoma: a comprehensive review..Int J Mol Sci2017;18:pli:E1960 PMCID:PMC5618609

[23] Lee DH,Di Vizio D.Induction of p53-independent apoptosis by ectopic expression of HOXA5 in human liposarcomas..Sci Rep2015;5:12580 PMCID:PMC4518222

[24] Lee DH,Goff C,Said JW.Overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival..Oncogenesis2013;2:e47 PMCID:PMC3671123

[25] Boro A,Born W.Plasma levels of miRNA-155 as a powerful diagnostic marker for dedifferentiated liposarcoma..Am J Cancer Res2016;6:544-52 PMCID:PMC4859679

[26] Zhang P,Liu J,Peng T.MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling..Cancer Res.2012;72:1751-62 PMCID:PMC3319789

[27] Ugras S,Jacobsen A,Socci ND.Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma..Cancer Res2011;71:5659-69 PMCID:PMC3165140

[28] Mazzu YZ,Soni RK,Qin L-X.miR-193b-regulated signaling networks serve as tumor suppressors in liposarcoma and promote adipogenesis in adipose-derived stem cells..Cancer Res2017;77:5728-40

[29] Yu PY,Braggio D,Bill KLJ.miR-133a function in the pathogenesis of dedifferentiated liposarcoma..Cancer Cell Int2018;18:89 PMCID:PMC6019219

[30] Manji GA.Managing liposarcomas: cutting through the fat..J Oncol Pract2016;12:221-7

[31] Kilpatrick SE,Choong PFM,Nascimento AG.The clinicopathologic spectrum of myxoid and round cell liposarcoma: a study of 95 cases..Cancer1996;77:1450-8

[32] Antonescu CR,Healey JH,Lui MY.Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements..Clin Cancer Res2000;6:2788-93

[33] Antonescu CR,Decuseara R,Woodruff JM.Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma..Clin Cancer Res2001;7:3977-87

[34] Jones RL,Al-Muderis O.Differential sensitivity of liposarcoma subtypes to chemotherapy..Eur J Cancer2005;41:2853-60

[35] Pollack SM,Hoch BL,Bleakley M.NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma..Cancer2012;118:4564-70 PMCID:PMC3361576

[36] Panagopoulos I,Isaksson M.A novel FUS/CHOP chimera in myxoid liposarcoma..Biochem Biophys Res Commun2000;279:838-45

[37] Kuroda M,Takanashi M,Machinami R.Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein..Am J Pathol1997;151:735-44 PMCID:PMC1857848

[38] Adelmant G,Freytag SO.Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function..J Biol Chem1998;273:15574-81

[39] Demicco EG,Ghadimi MP,Bolshakov S.Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma..Mod Pathol2012;25:212-21 PMCID:PMC3266971

[40] Lim J,Nielsen TO.New strategies in sarcoma: linking genomic and immunotherapy approaches to molecular subtype..Clin Cancer Res2015;21:4753-9

[41] Pollack SM.The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients..Expert Rev Vaccines2018;17:107-14 PMCID:PMC6521962

[42] Davidović R,Mandušić V,Stanojević M.p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma..Med Oncol2013;30:682

[43] Oda Y,Takahira T,Kawaguchi K.Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis..J Pathol2005;207:410-21

[44] De Cecco L,Brich S,Bozzi F.Identification of a gene expression driven progression pathway in myxoid liposarcoma..Oncotarget2014;5:5965-77 PMCID:PMC4171605

[45] Borjigin N,Wu W,Suzuki R.TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma..Biochem Biophys Res Commun2012;427:355-60

[46] Bajou K,Jost M,Gils A.Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth..Oncogene2004;23:6986-90

[47] Ghadimi MP,Peng T,Young ED.Pleomorphic liposarcoma: Clinical observations and molecular variables..Cancer2011;117:5359-69 PMCID:PMC3161152

[48] Hornick JL,Mentzel T,Oliveira AM.Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases..Am J Surg Pathol2004;28:1257-67

[49] Dalal KM,Antonescu CR,Singer S.Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk..Ann Surg2006;24:381-91 PMCID:PMC1856537

[50] Gebhard S,Michels JJ,Bertrand G.Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group..Am J Surg Pathol.2002;26:601-16

[51] Dei Tos AP.Liposarcomas: diagnostic pitfalls and new insights..Histopathology2014;64:38-52

[52] Taylor BS,Socci ND,Ladanyi M.Functional copy-number alterations in cancer..PLoS One2008;3:e3179 PMCID:PMC2527508

[53] Livingston JA,Barbo A,Madewell JE.Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard..Sci Rep2017;7:1-8 PMCID:PMC5428335

[54] Singer S,Riedel E.Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma..Ann Surg2003;238:358-70discussion 370-1 PMCID:PMC1422708

[55] Dalal KM,Singer S.Diagnosis and management of lipomatous tumors..J Surg Oncol2008;97:298-313

[56] Italiano A,Cioffi A,Isambert N.Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival..Ann Oncol2012;23:1601-7

[57] Ratan R.Chemotherapy for soft tissue sarcoma..Cancer2016;18:604-10

[58] McGovern Y,Jones RL.Systemic therapy in metastatic or unresectable well-differentiated/dedifferentiated liposarcoma..Front Oncol2017;7:292 PMCID:PMC5715199

[59] Demetri GD,Jones RL,Schuetze SM.Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial..J Clin Oncol2016;34:786-93 PMCID:PMC5070559

[60] Ratan R.Trabectedin and eribulin: where do they fit in the management of soft tissue sarcoma?.Curr Treat Options Oncol2017;18:1-9

[61] Jones RL,Schuetze SM,Elias A.Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma..Ann Oncol2018;29:1995-2002 PMCID:PMC6454486

[62] Demetri GD,Grignani G,Maki RG.Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine..J Clin Oncol2017;35:3433-9

[63] Setola E,Benson C,Palmerini E.Eribulin in advanced liposarcoma and leiomyosarcoma..Expert Rev Anticancer Ther2017;17:717-23

[64] Schöffski P,Maki RG,Gelderblom H.Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial..Lancet2016;387:1629-37

[65] Maki RG.Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future..Oncologist.2007;12:999-1006

[66] Pollack SM,Spraker MB.Emerging targeted and immune-based therapies in sarcoma..J Clin Oncol2018;36:125-35

[67] Wilky BA, Jones RL, Keedy VL. The current landscape of early drug development for patients with sarcoma. Am Soc Clin Oncol Educ B [Internet] 2017;37:807-10. Available from: http://meetinglibrary.asco.org/content/174701-199 [Last accessed on 25 Apr 2019]

[68] Nathenson MJ,Sausville E.Immunotherapy: a new (and Old) approach to treatment of soft tissue and bone sarcomas..Oncologist2018;23:71-83 PMCID:PMC5759816

[69] Samuels BL,Somaiah N,Skubitz KM.Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma..Cancer2017;123:4640-7

[70] Keung EZ.The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies..Surg Oncol Clin N Am.2018;

[71] Coley WBII.Contribution to the knowledge of sarcoma..Ann Surg1891;14:199-220 PMCID:PMC1428624

[72] Tawbi HA,Bolejack V,Schuetze SM.Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial..Lancet Oncol2017;18:1493-501

[73] D’Angelo SP,Van Tine BA,Milhem MM.Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials..Lancet Oncol2018;19:416-26 PMCID:PMC6126546

[74] D’Angelo SP, Druta M, Liebner DA, Schuetze S, Somaiah N, et al. Pilot study of NY-ESO-1^c259 T cells in advanced myxoid/round cell liposarcoma. J Clin Oncol 2018;36:3005. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.3005. [Last accessed on 25 Apr 2019]